Post-Surgical Indications to Radioiodine Treatment and Potential Risk Factors for Post-Treatment Recurrence in Patients with Intermediate-Risk Differentiated Thyroid Carcinoma.
differentiated thyroid carcinoma
intermediate-risk
radioiodine
recurrence
risk factors
thyroid cancer
Journal
Journal of personalized medicine
ISSN: 2075-4426
Titre abrégé: J Pers Med
Pays: Switzerland
ID NLM: 101602269
Informations de publication
Date de publication:
29 Apr 2023
29 Apr 2023
Historique:
received:
27
03
2023
revised:
20
04
2023
accepted:
28
04
2023
medline:
27
5
2023
pubmed:
27
5
2023
entrez:
27
5
2023
Statut:
epublish
Résumé
In this multicentric retrospective observational study, we investigated the potential risk factors for radioiodine (RAI) indication and the post-treatment recurrence of intermediate-risk differentiated thyroid cancer (DTC) 1 and 3 years from diagnosis. We included 121 patients who underwent thyroidectomy for intermediate-risk DTC. The 92 patients (76.0%) who underwent RAI treatment had a higher prevalence of extra-thyroid micro-extension (mETE) (
Identifiants
pubmed: 37240945
pii: jpm13050775
doi: 10.3390/jpm13050775
pmc: PMC10220588
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Eur Thyroid J. 2018 Aug;7(4):211-217
pubmed: 30283740
Clin Nucl Med. 2012 Nov;37(11):1069-74
pubmed: 22996253
Arch Otolaryngol Head Neck Surg. 2012 Dec 1;138(12):1141-6
pubmed: 23403514
Clin Endocrinol (Oxf). 2021 Dec;95(6):901-908
pubmed: 34185324
Thyroid. 2020 Jul;30(7):1008-1016
pubmed: 32059626
Lancet Diabetes Endocrinol. 2019 Jan;7(1):44-51
pubmed: 30501974
Nucl Med Mol Imaging. 2016 Dec;50(4):329-336
pubmed: 27994688
CA Cancer J Clin. 2017 Mar;67(2):93-99
pubmed: 28094848
Thyroid. 2016 Jan;26(1):1-133
pubmed: 26462967
Nucl Med Commun. 2016 Feb;37(2):110-5
pubmed: 26513055
Front Endocrinol (Lausanne). 2020 Jul 10;11:381
pubmed: 32754115
Thyroid. 2016 Sep;26(9):1156-66
pubmed: 27480110
Endocrine. 2015 Sep;50(1):130-7
pubmed: 25792004
Endocrine. 2016 Jun;52(3):579-86
pubmed: 26708045
Thyroid. 2016 Aug;26(8):1110-6
pubmed: 27302111
Ann Surg Oncol. 2012 Jun;19(6):1874-80
pubmed: 22065195
PLoS One. 2018 Aug 17;13(8):e0202644
pubmed: 30118516
Ann Surg Oncol. 2018 Oct;25(11):3193-3199
pubmed: 30039325
J Endocrinol Invest. 2019 Jun;42(6):687-692
pubmed: 30353424
Cancers (Basel). 2020 Nov 13;12(11):
pubmed: 33202736
N Engl J Med. 2022 Mar 10;386(10):923-932
pubmed: 35263518
J Clin Endocrinol Metab. 2018 Mar 01;:
pubmed: 29506045
Ann Surg Oncol. 2021 Nov;28(12):7533-7544
pubmed: 34043093
Thyroid. 2021 Dec;31(12):1814-1821
pubmed: 34541894
Ann Oncol. 2019 Dec 1;30(12):1856-1883
pubmed: 31549998
Ann Otol Rhinol Laryngol. 2006 Aug;115(8):607-10
pubmed: 16944659
J Int Med Res. 2020 Nov;48(11):300060520966491
pubmed: 33213252
Clin Endocrinol (Oxf). 2017 Mar;86(3):438-443
pubmed: 27731521
Thyroid. 2018 Aug;28(8):982-990
pubmed: 29936892
Endocr Relat Cancer. 2006 Dec;13(4):1159-72
pubmed: 17158761
J Endocrinol Invest. 2018 Sep;41(9):1029-1035
pubmed: 29470826
N Engl J Med. 2012 May 3;366(18):1674-85
pubmed: 22551128